MIF as a disease target: ISO-1 as a proof-of-concept therapeutic

Bibliography

• 1  Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science153(731),80–82 (1966).
  Medline CASGoogle Scholar
• 2  David JR. Delayed hypersensitivity in vitro. Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl Acad. Sci. USA56(1),72–77 (1966).
  Medline CASGoogle Scholar
• 3  Bucala R. MIF rediscovered: cytokine, pituitary hormone and glucocorticoid-induced regulator of the immune response. FASEB J.10(14),1607–1613 (1996).
  Medline CASGoogle Scholar
• 4  Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med.179(6),1895–1902 (1994).
  Medline CASGoogle Scholar
• 5  Bernhagen J, Calandra T, Mitchell RA et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature365(6448),756–759 (1993).
  Medline CASGoogle Scholar
• 6  Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G. Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle6(9),1030–1034 (2007).
  Medline CASGoogle Scholar
• 7  Calandra T, Bucala R. Macrophage migration inhibitory factor (MIF). A glucocorticoid counter-regulator within the immune system. Crit. Rev. Immunol.17(1),77–88 (1997).
  Medline CASGoogle Scholar
• 8  Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J. Biol. Chem.275(1),444–450 (2000).
  Medline CASGoogle Scholar
• 9  Assuncao-Miranda I, Amaral FA, Bozza FA et al. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J.24(1),218–228 (2010).
  MedlineGoogle Scholar
• 10  Petrovsky N, Socha L, Silva D, Grossman AB, Metz C, Bucala R. Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol. Cell Biol.81(2),137–143 (2003).
  Medline CASGoogle Scholar
• 11  Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad. Regulation of inflammation and immunity. Mol. Endocrinol.21(6),1267–1280 (2007).
  Medline CASGoogle Scholar
• 12  Daun JM, Cannon JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IκBα. Am. J. Physiol. Regul. Integr. Comp. Physiol.279(3),R1043–1049 (2000).
  Medline CASGoogle Scholar
• 13  Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur. J. Immunol.35(12),3405–3413 (2005).
  Medline CASGoogle Scholar
• 14  Aeberli D, Yang Y, Mansell A, Santos L, Leech M, Morand EF. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett.580(3),974–981 (2006).
  Medline CASGoogle Scholar
• 15  Calandra T, Bucala R. Macrophage migration inhibitory factor. A counter-regulator of glucocorticoid action and critical mediator of septic shock. J. Inflamm.47(1–2),39–51 (1995).
  Medline CASGoogle Scholar
• 16  Al-Abed Y, Dabideen D, Aljabari B et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem.280(44),36541–36544 (2005).
  Medline CASGoogle Scholar
• 17  Hou XQ, Gao YW, Yang ST, Wang CY, Ma ZY, Xia XZ. Role of macrophage migration inhibitory factor in influenza H5N1 virus pneumonia. Acta Virol.53(4),225–231 (2009).
  Medline CASGoogle Scholar
• 18  Stosic-Grujicic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun. Rev.8(3),244–249 (2009).
  Medline CASGoogle Scholar
• 19  Greven D, Leng L, Bucala R. Autoimmune diseases. MIF as a therapeutic target. Expert Opin. Ther. Targets14(3),253–264 (2010).
  Medline CASGoogle Scholar
• 20  Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Natl Acad. Sci. USA93(11),5191–5196 (1996).
  Medline CASGoogle Scholar
• 21  Sugimoto H, Suzuki M, Nakagawa A, Tanaka I, Nishihira J. Crystal structure of macrophage migration inhibitory factor from human lymphocyte at 2.1 a resolution. FEBS Lett.389(2),145–148 (1996).
  Medline CASGoogle Scholar
• 22  Suzuki M, Sugimoto H, Nakagawa A, Tanaka I, Nishihira J, Sakai M. Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat. Struct. Biol.3(3),259–266 (1996).
  Medline CASGoogle Scholar
• 23  Swope MD, Sun HW, Klockow B, Blake P, Lolis E. Macrophage migration inhibitory factor interactions with glutathione and s-hexylglutathione. J. Biol. Chem.273(24),14877–14884 (1998).
  Medline CASGoogle Scholar
• 24  Bendrat K, Al-Abed Y, Callaway DJ et al. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry36(49),15356–15362 (1997).
  Medline CASGoogle Scholar
• 25  Lubetsky JB, Dios A, Han J et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem.277(28),24976–24982 (2002).
  Medline CASGoogle Scholar
• 26  Swope M, Sun HW, Blake PR, Lolis E. Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J.17(13),3534–3541 (1998).
  Medline CASGoogle Scholar
• 27  Dios A, Mitchell RA, Aljabari B et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem.45(12),2410–2416 (2002).
  Medline CASGoogle Scholar
• 28  Cheng KF, Al-Abed Y. Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg. Med. Chem. Lett.16(13),3376–3379 (2006).
  Medline CASGoogle Scholar
• 29  Dabideen DR, Cheng KF, Aljabari B, Miller EJ, Pavlov VA, Al-Abed Y. Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. J. Med. Chem.50(8),1993–1997 (2007).
  Medline CASGoogle Scholar
• 30  Crichlow GV, Cheng KF, Dabideen D et al. Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J. Biol. Chem.282(32),23089–23095 (2007).
  Medline CASGoogle Scholar
• 31  Dagia NM, Kamath DV, Bhatt P et al. A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis. Eur. J. Pharmacol.607(1–3),201–212 (2009).
  Medline CASGoogle Scholar
• 32  Balachandran S, Rodge A, Gadekar PK et al. Novel derivatives of iso-1 as potent inhibitors of MIF biological function. Bioorg. Med. Chem. Lett.19(16),4773–4776 (2009).
  Medline CASGoogle Scholar
• 33  Winner M, Meier J, Zierow S et al. A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res.68(18),7253–7257 (2008).
  Medline CASGoogle Scholar
• 34  Cournia Z, Leng L, Gandavadi S, Du X, Bucala R, Jorgensen WL. Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J. Med. Chem.52(2),416–424 (2009).
  Medline CASGoogle Scholar
• 35  Ouertatani-Sakouhi H, El-Turk F, Fauvet B et al. Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J. Biol. Chem.285,26581–26598 (2010).
  Medline CASGoogle Scholar
• 36  Cho Y, Crichlow GV, Vermeire JJ et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc. Natl Acad. Sci. USA107(25),11313–11318 (2010).
  Medline CASGoogle Scholar
• 37  Hare AA, Leng L, Gandavadi S et al. Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg. Med. Chem. Lett.20(19),5811–5814 (2010).
  Medline CASGoogle Scholar
• 38  Arndt U, Wennemuth G, Barth P et al. Release of macrophage migration inhibitory factor and cxcl8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection. J. Virol.76(18),9298–9306 (2002).
  Medline CASGoogle Scholar
• 39  Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of du-145 prostate cancer cells. J. Immunol.177(12),8730–8739 (2006).
  Medline CASGoogle Scholar
• 40  Cho Y, Jones BF, Vermeire JJ et al. Structural and functional characterization of a secreted hookworm macrophage migration inhibitory factor (MIF) that interacts with the human MIF receptor CD74. J. Biol. Chem.282(32),23447–23456 (2007).
  Medline CASGoogle Scholar
• 41  Rendon BE, Roger T, Teneng I et al. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J. Biol. Chem.282(41),29910–29918 (2007).
  Medline CASGoogle Scholar
• 42  Binsky I, Haran M, Starlets D et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc. Natl Acad. Sci. USA104(33),13408–13413 (2007).
  Medline CASGoogle Scholar
• 43  Stojanovic I, Maksimovic-Ivanic D, Al-Abed Y, Nicoletti F, Stosic-Grujicic S. Control of the final stage of immune-mediated diabetes by ISO-1, an antagonist of macrophage migration inhibitory factor. Arch. Biol. Sci.60(3),389–402 (2008).
  Google Scholar
• 44  West PW, Parker LW, Ward JR, Sabroe I. Differential and cell-type specific regulation of responses to toll-like receptor agonists by ISO-1. Immunology125(1),101–110 (2008).
  Medline CASGoogle Scholar
• 45  He XX, Chen K, Yang J et al. Macrophage migration inhibitory factor promotes colorectal cancer. Mol. Med.15(1–2),1–10 (2009).
  Medline CASGoogle Scholar
• 46  Dhanantwari P, Nadaraj S, Kenessey A et al. Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochem. Biophys. Res. Commun.371(2),298–303 (2008).
  Medline CASGoogle Scholar
• 47  Gore Y, Starlets D, Maharshak N et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74–CD44 receptor complex. J. Biol. Chem.283(5),2784–2792 (2008).
  Medline CASGoogle Scholar
• 48  Takahashi K, Koga K, Linge HM et al. Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir. Res.10,33 (2009).
  MedlineGoogle Scholar
• 49  Barrilleaux BL, Phinney DG, Fischer-Valuck BW et al. Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells. Tissue Eng. Part. A15(9),2335–2346 (2009).
  Medline CASGoogle Scholar
• 50  Piette C, Deprez M, Roger T, Noel A, Foidart JM, Munaut C. The dexamethasone-induced inhibition of proliferation, migration and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors. J. Biol. Chem.284(47),32483–32492 (2009).
  Medline CASGoogle Scholar
• 51  Schrader J, Deuster O, Rinn B et al. Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer9,464 (2009).
  MedlineGoogle Scholar
• 52  Carli C, Metz CN, Al-Abed Y, Naccache PH, Akoum A. Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor. Involvement of novel kinase signaling pathways. Endocrinology150(7),3128–3137 (2009).
  Medline CASGoogle Scholar
• 53  Fischer-Valuck BW, Barrilleaux BL, Phinney DG, Russell KC, Prockop DJ, O’Connor KC. Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. Biotechnol. Lett.32(1),19–27 (2010).
  Medline CASGoogle Scholar
• 54  Bacher M, Deuster O, Aljabari B et al. The role of macrophage migration inhibitory factor in Alzheimer’s disease. Mol. Med.16(3–4),116–121 (2010).
  Medline CASGoogle Scholar
• 55  Binsky I, Lantner F, Grabovsky V et al. Tap63 regulates vla-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J. Immunol.184(9),4761–4769 (2010).
  Medline CASGoogle Scholar
• 56  Assuncao-Miranda I, Bozza MT, Da Poian AT. Pro-inflammatory response resulting from sindbis virus infection of human macrophages. Implications for the pathogenesis of viral arthritis. J. Med. Virol.82(1),164–174 (2010).
  Medline CASGoogle Scholar
• 57  Dessein AF, Stechly L, Jonckheere N et al. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res.70(11),4644–4654 (2010).
  Medline CASGoogle Scholar
• 58  Huang MC, Patel K, Taub DD, Longo DL, Goetzl EJ. Human CD4- 8- T cells are a distinctive immunoregulatory subset. FASEB J.24(7),2558–2566 (2010).
  Medline CASGoogle Scholar
• 59  Liang JL, Xiao DZ, Liu XY et al. High glucose induces apoptosis in ac16 human cardiomyocytes via macrophage migration inhibitory factor and c-jun N-terminal kinase. Clin. Exp. Pharmacol. Physiol.37(10),969–973 (2010).
  Medline CASGoogle Scholar
• 60  Veillat V, Carli C, Metz CN, Al-Abed Y, Naccache PH, Akoum A. Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74 and MAPK signaling pathways. Mol. Endocrinol.24(10),2070–2071 (2010).
  Google Scholar
• 61  Chuang CC, Chuang YC, Chang WT et al. Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-κ β activation during Vibrio vulnificus infection. BMC Immunol.11,50 (2010).
  MedlineGoogle Scholar
• 62  Cvetkovic I, Al-Abed Y, Miljkovic D et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology146(7),2942–2951 (2005).
  Medline CASGoogle Scholar
• 63  Nicoletti F, Creange A, Orlikowski D et al. Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain–Barre syndrome and experimental allergic neuritis. J. Neuroimmunol.168(1–2),168–174 (2005).
  Medline CASGoogle Scholar
• 64  Sakuragi T, Lin X, Metz CN et al. Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg. Infect. (Larchmt)8(1),29–40 (2007).
  MedlineGoogle Scholar
• 65  Arjona A, Foellmer HG, Town T et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J. Clin. Invest.117(10),3059–3066 (2007).
  Medline CASGoogle Scholar
• 66  Shah YM, Ito S, Morimura K et al. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology134(7),2036–2048 (2008).
  MedlineGoogle Scholar
• 67  Wang F, Shen X, Guo X et al. Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats. Pain148(2),275–283 (2010).
  Medline CASGoogle Scholar
• 68  Chen PF, Luo YL, Wang W et al. ISO-1, an MIF antagonist, inhibits airway remodeling in a murine model of chronic asthma. Mol. Med.16(9-10),400–8. (2010).
  Medline CASGoogle Scholar
• 69  Conboy L, Varea E, Castro JE et al. Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol. Psychiatry DOI: 10.1038/mp.2010.15 (2010). (Epub ahead of print).
  MedlineGoogle Scholar
• 70  Vera PL, Iczkowski KA, Howard DJ, Jiang L, Meyer-Siegler KL. Antagonism of macrophage migration inhibitory factor decreases cyclophosphamide cystitis in mice. Neurourol. Urodyn.29(8),1451–1457 (2010).
  Medline CASGoogle Scholar
• 71  Traggiai E, Casati A, Frascoli M et al. Selective preservation of bone marrow mature recirculating but not marginal zone B cells in murine models of chronic inflammation. PLoS One5(6),e11262 (2010).
  MedlineGoogle Scholar
• 72  Kithcart AP, Cox GM, Sielecki T et al. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J.24(11),4459–4466 (2010).
  Medline CASGoogle Scholar
• 73  Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A et al. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J.24(7),2583–2590 (2010).
  Medline CASGoogle Scholar
• 74  Gadjeva M, Nagashima J, Zaidi T, Mitchell RA, Pier GB. Inhibition of macrophage migration inhibitory factor ameliorates ocular Pseudomonas aeruginosa-induced keratitis. PLoS Pathog.6(3),e1000826 (2010).
  MedlineGoogle Scholar
• 75  Leng L, Bucala R. Insight into the biology of macrophage migration inhibitory factor (MIF) revealed by the cloning of its cell surface receptor. Cell Res.16(2),162–168 (2006).
  Medline CASGoogle Scholar
• 76  Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a taf(ii)105-Nf-κB-dependent transcription program. J. Biol. Chem.276(29),27203–27206 (2001).
  Medline CASGoogle Scholar
• 77  Matza D, Lantner F, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc. Natl Acad. Sci. USA99(5),3018–3023 (2002).
  Medline CASGoogle Scholar
• 78  Anderson HA, Bergstralh DT, Kawamura T, Blauvelt A, Roche PA. Phosphorylation of the invariant chain by protein kinase C regulates MHC class II trafficking to antigen-processing compartments. J. Immunol.163(10),5435–5443 (1999).
  Medline CASGoogle Scholar
• 79  Kleemann R, Hausser A, Geiger G et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through JAB1. Nature408(6809),211–216 (2000).
  Medline CASGoogle Scholar
• 80  Bernhagen J, Krohn R, Lue H et al. Mif is a noncognate ligand of cxc chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med.13(5),587–596 (2007).
  Medline CASGoogle Scholar
• 81  Weber C, Kraemer S, Drechsler M et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc. Natl Acad. Sci. USA105(42),16278–16283 (2008).
  Medline CASGoogle Scholar
• 82  Schwartz V, Lue H, Kraemer S et al. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett.583(17),2749–2757 (2009).
  Medline CASGoogle Scholar
• 83  Filip AM, Klug J, Cayli S et al. Ribosomal protein s19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function. J. Biol. Chem.284(12),7977–7985 (2009).
  Medline CASGoogle Scholar
• 84  Calandra T, Echtenacher B, Roy DL et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med.6(2),164–170 (2000).
  Medline CASGoogle Scholar
• 85  Radstake TR, Sweep FC, Welsing P et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum.52(10),3020–3029 (2005).
  Medline CASGoogle Scholar
• 86  Kim HR, Park MK, Cho ML et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J. Rheumatol.34(5),927–936 (2007).
  Medline CASGoogle Scholar
• 87  Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J. Rheumatol.31(2),268–273 (2004).
  Medline CASGoogle Scholar
• 88  Sanchez E, Gomez LM, Lopez-Nevot MA et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun.7(5),433–436 (2006).
  Medline CASGoogle Scholar
• 89  Rinta S, Kuusisto H, Raunio M et al. Apoptosis-related molecules in blood in multiple sclerosis. J. Neuroimmunol.205(1–2),135–141 (2008).
  Medline CASGoogle Scholar
• 90  Akcali A, Pehlivan S, Pehlivan M, Sever T, Neyal M. Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J. Int. Med. Res.38(1),69–77 (2010).
  Medline CASGoogle Scholar
• 91  Shimizu T, Nishihira J, Mizue Y et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J. Invest. Dermatol.116(6),989–990 (2001).
  Medline CASGoogle Scholar
• 92  Donn RP, Plant D, Jury F et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J. Invest. Dermatol.123(3),484–487 (2004).
  Medline CASGoogle Scholar
• 93  Morin M, Bellehumeur C, Therriault MJ, Metz C, Maheux R, Akoum A. Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis. Fertil. Steril.83(4),865–872 (2005).
  Medline CASGoogle Scholar
• 94  Herder C, Kolb H, Koenig W et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes. Results from the cooperative health research in the region of augsburg, survey 4 (KORA S4). Diabetes Care29(2),368–371 (2006).
  Medline CASGoogle Scholar
• 95  Herder C, Klopp N, Baumert J et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes. Results from the MONICA/KORA augsburg case–cohort study, 1984–2002. Diabetologia51(2),276–284 (2008).
  Medline CASGoogle Scholar
• 96  Burger-Kentischer A, Goebel H, Seiler R et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation105(13),1561–1566 (2002).
  Medline CASGoogle Scholar
• 97  Glintborg D, Andersen M, Richelsen B, Bruun JM. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α are increased in patients with polycystic ovary syndrome (pcos) and associated with adiposity, but unaffected by pioglitazone treatment. Clin. Endocrinol. (Oxf.)71(5),652–658 (2009).
  Medline CASGoogle Scholar
• 98  Gonzalez F, Rote NS, Minium J, Weaver AL, Kirwan JP. Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. Cytokine51(3),240–244 (2010).
  Medline CASGoogle Scholar
• 99  Yamaguchi E, Nishihira J, Shimizu T et al. Macrophage migration inhibitory factor (MIF) in bronchial asthma. Clin. Exp. Allergy30(9),1244–1249 (2000).
  Medline CASGoogle Scholar
• 100  Robroeks CM, Rijkers GT, Jobsis Q et al. Increased cytokines, chemokines and soluble adhesion molecules in exhaled breath condensate of asthmatic children. Clin. Exp. Allergy40(1),77–84 (2010).
  Medline CASGoogle Scholar
• 101  Lee H, Rhee H, Kang HJ et al. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am. J. Clin. Pathol.129(5),772–779 (2008).
  MedlineGoogle Scholar
• 102  Xia HH, Yang Y, Chu KM et al. Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer115(23),5441–5449 (2009).
  Medline CASGoogle Scholar
• 103  Yende S, Angus DC, Kong L et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J.23(8),2403–2411 (2009).
  Medline CASGoogle Scholar
• 104  Baugh JA, Chitnis S, Donnelly SC et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun.3(3),170–176 (2002).
  Medline CASGoogle Scholar
• 105  Fei BY, Lv HX, Yang JM, Ye ZY. Association of MIF-173 gene polymorphism with inflammatory bowel disease in Chinese han population. Cytokine41(1),44–47 (2008).
  Medline CASGoogle Scholar
• 106  Sakaue S, Ishimaru S, Hizawa N et al. Promoter polymorphism in the macrophage migration inhibitory factor gene is associated with obesity. Int. J. Obes. (Lond.)30(2),238–242 (2006).
  Medline CASGoogle Scholar
• 107  Wu J, Fu S, Ren X et al. Association of MIF promoter polymorphisms with childhood asthma in a northeastern chinese population. Tissue Antigens73(4),302–306 (2009).
  Medline CASGoogle Scholar
• 108  Xue Y, Xu H, Rong L et al. The MIF -173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk. Res.34(10),1282–1286 (2010).
  Medline CASGoogle Scholar
• 109  Meyer-Siegler KL, Vera PL, Iczkowski KA et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun.8(8),646–652 (2007).
  Medline CASGoogle Scholar
• 110  Ding GX, Zhou SQ, Xu Z et al. The association between MIF-173 G>C polymorphism and prostate cancer in southern chinese. J. Surg. Oncol.100(2),106–110 (2009).
  Medline CASGoogle Scholar
• 111  Tsianos EV, Katsanos K. Do we really understand what the immunological disturbances in inflammatory bowel disease mean? World J. Gastroenterol.15(5),521–525 (2009).
  Medline CASGoogle Scholar
• 112  Ishiguro Y, Ohkawara T, Sakuraba H et al. Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin. Immunol.120(3),335–341 (2006).
  Medline CASGoogle Scholar
• 113  Ohkawara T, Nishihira J, Takeda H et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology123(1),256–270 (2002).
  Medline CASGoogle Scholar
• 114  Ohkawara T, Miyashita K, Nishihira J et al. Transgenic over-expression of macrophage migration inhibitory factor renders mice markedly more susceptible to experimental colitis. Clin. Exp. Immunol.140(2),241–248 (2005).
  Medline CASGoogle Scholar
• 115  Ohkawara T, Nishihira J, Ishiguro Y et al. Resistance to experimental colitis depends on cytoprotective heat shock proteins in macrophage migration inhibitory factor null mice. Immunol. Lett.107(2),148–154 (2006).
  Medline CASGoogle Scholar
• 116  DeJong YP, Abadia-Molina AC, Satoskar AR et al. Development of chronic colitis is dependent on the cytokine MIF. Nat. Immunol.2(11),1061–1066 (2001).
  Medline CASGoogle Scholar
• 117  Bojunga J, Kusterer K, Bacher M, Kurek R, Usadel KH, Renneberg H. Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice. Cytokine21(4),179–186 (2003).
  Medline CASGoogle Scholar
• 118  Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D et al. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J. Cell Physiol.215(3),665–675 (2008).
  Medline CASGoogle Scholar
• 119  Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes52(5),1137–1142 (2003).
  Medline CASGoogle Scholar
• 120  Smolen JS, Aletaha D. Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res. Ther.11(1),204 (2009).
  MedlineGoogle Scholar
• 121  Mrowietz U, Reich K. Psoriasis – new insights into pathogenesis and treatment. Dtsch. Arztebl. Int.106(1–2),11–19 (2009).
  MedlineGoogle Scholar
• 122  Wijbrandts CA, Van Leuven SI, Boom HD et al. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann. Rheum. Dis.68(8),1316–1321 (2009).
  Medline CASGoogle Scholar
• 123  Morand EF, Leech M, Weedon H, Metz C, Bucala R, Smith MD. Macrophage migration inhibitory factor in rheumatoid arthritis. Clinical correlations. Rheumatology (Oxford)41(5),558–562 (2002).
  Medline CASGoogle Scholar
• 124  Steinhoff M, Meinhardt A, Steinhoff A, Gemsa D, Bucala R, Bacher M. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br. J. Dermatol.141(6),1061–1066 (1999).
  Medline CASGoogle Scholar
• 125  Leech M, Metz C, Santos L et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum.41(5),910–917 (1998).
  Medline CASGoogle Scholar
• 126  Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J. Immunol.158(11),5514–5517 (1997).
  Medline CASGoogle Scholar
• 127  Pakozdi A, Amin MA, Haas CS et al. Macrophage migration inhibitory factor. A mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res. Ther.8(4),R132 (2006).
  MedlineGoogle Scholar
• 128  Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-behcet’s disease. J. Neurol. Sci.179(S1–S2),127–131 (2000).
  Medline CASGoogle Scholar
• 129  Denkinger CM, Denkinger M, Kort JJ, Metz C, Forsthuber TG. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J. Immunol.170(3),1274–1282 (2003).
  Medline CASGoogle Scholar
• 130  Powell ND, Papenfuss TL, McClain MA et al. Cutting edge. Macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J. Immunol.175(9),5611–5614 (2005).
  Medline CASGoogle Scholar
• 131  Creange A, Sharshar T, Planchenault T et al. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain–Barre syndrome. Neurology53(8),1683–1691 (1999).
  Medline CASGoogle Scholar
• 132  Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ. Experimental therapeutic strategies for severe sepsis. Mediators and mechanisms. Ann. NY Acad. Sci.1144,210–236 (2008).
  Medline CASGoogle Scholar
• 133  Bernhagen J, Calandra T, Bucala R. The emerging role of MIF in septic shock and infection. Biotherapy8(2),123–127 (1994).
  Medline CASGoogle Scholar
• 134  Emonts M, Sweep FC, Grebenchtchikov N et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin. Infect. Dis.44(10),1321–1328 (2007).
  Medline CASGoogle Scholar
• 135  Bozza M, Satoskar AR, Lin G et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med.189(2),341–346 (1999).
  Medline CASGoogle Scholar
• 136  Medvedev AE, Henneke P, Schromm A et al. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/cd14 cells is not affected by overexpression of toll-like receptors 2 or 4. J. Immunol.167(4),2257–2267 (2001).
  Medline CASGoogle Scholar
• 137  Roger T, David J, Glauser MP, Calandra T. Mif regulates innate immune responses through modulation of toll-like receptor 4. Nature414(6866),920–924 (2001).
  Medline CASGoogle Scholar
• 138  Roger T, Froidevaux C, Martin C, Calandra T. Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of toll-like receptor 4 (TLR4). J. Endotoxin Res.9(2),119–123 (2003).
  Medline CASGoogle Scholar
• 139  Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect. Immun.77(2),568–575 (2009).
  Medline CASGoogle Scholar
• 140  Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur. Respir. J.20(4),990–995 (2002).
  Medline CASGoogle Scholar
• 141  Yende S, D’angelo G, Kellum JA et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am. J. Respir. Crit. Care Med.177(11),1242–1247 (2008).
  MedlineGoogle Scholar
• 142  De Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza a (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med.12(10),1203–1207 (2006).
  Medline CASGoogle Scholar
• 143  Getts MT, Miller SD. 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders. Triggering of autoimmune diseases by infections. Clin. Exp. Immunol.160(1),15–21 (2010).
  Medline CASGoogle Scholar
• 144  Hamdulay SS, Glynne SJ, Keat A. When is arthritis reactive? Postgrad. Med. J.82(969),446–453 (2006).
  Medline CASGoogle Scholar
• 145  Vassilopoulos D, Calabrese LH. Virally associated arthritis 2008. Clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res. Ther.10(5),215 (2008).
  MedlineGoogle Scholar
• 146  Mcinnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol.7(6),429–442 (2007).
  Medline CASGoogle Scholar
• 147  Santos LL, Morand EF. Macrophage migration inhibitory factor. A key cytokine in RA, SLE and atherosclerosis. Clin. Chim. Acta399(1–2),1–7 (2009).
  Medline CASGoogle Scholar
• 148  Lidbury BA, Rulli NE, Suhrbier A et al. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J. Infect. Dis.197(11),1585–1593 (2008).
  Medline CASGoogle Scholar
• 149  Heise CE, O’Dowd BF, Figueroa DJ et al. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem.275(39),30531–30536 (2000).
  Medline CASGoogle Scholar
• 150  Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J. Virol.80(2),737–749 (2006).
  Medline CASGoogle Scholar
• 151  Lidbury BA, Simeonovic C, Maxwell GE, Marshall ID, Hapel AJ. Macrophage-induced muscle pathology results in morbidity and mortality for ross river virus-infected mice. J. Infect. Dis.181(1),27–34 (2000).
  Medline CASGoogle Scholar
• 152  Ginsberg HN, Maccallum PR. The obesity, metabolic syndrome and type 2 diabetes mellitus pandemic. Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J. Cardiometab. Syndr.4(2),113–119 (2009).
  MedlineGoogle Scholar
• 153  Navarro JF, Mora C, Gomez M, Muros M, Lopez-Aguilar C, Garcia J. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-α and interleukin-6 in type 2 diabetic patients. Nephrol. Dial. Transplant.23(3),919–926 (2008).
  Medline CASGoogle Scholar
• 154  Herder C, Peltonen M, Koenig W et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes. Results from the Finnish Diabetes Prevention study. Diabetes55(8),2340–2346 (2006).
  Medline CASGoogle Scholar
• 155  Yabunaka N, Nishihira J, Mizue Y et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care23(2),256–258 (2000).
  Medline CASGoogle Scholar
• 156  Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-α and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol.18(8),1199–1202 (1998).
  Medline CASGoogle Scholar
• 157  Katsuki A, Sumida Y, Murashima S et al. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab.83(3),859–862 (1998).
  Medline CASGoogle Scholar
• 158  Kleemann R, Bucala R. Macrophage migration inhibitory factor. Critical role in obesity, insulin resistance and associated comorbidities. Mediators Inflamm. 2010:610479 (2010) (Epub).
  MedlineGoogle Scholar
• 159  Waeber G, Calandra T, Roduit R et al. Insulin secretion is regulated by the glucose-dependent production of islet β cell macrophage migration inhibitory factor. Proc. Natl Acad. Sci. USA94(9),4782–4787 (1997).
  Medline CASGoogle Scholar
• 160  Mitchell RA, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin. Cancer Biol.10(5),359–366 (2000).
  Medline CASGoogle Scholar
• 161  Sun B, Nishihira J, Yoshiki T et al. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the rho-dependent pathway. Clin. Cancer Res.11(3),1050–1058 (2005).
  Medline CASGoogle Scholar
• 162  Fingerle-Rowson G, Petrenko O, Metz CN et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc. Natl Acad. Sci. USA100(16),9354–9359 (2003).
  Medline CASGoogle Scholar
• 163  Takahashi N, Nishihira J, Sato Y et al. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med.4(11),707–714 (1998).
  Medline CASGoogle Scholar
• 164  Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J. Immunol.160(12),5693–5696 (1998).
  Medline CASGoogle Scholar
• 165  Kundu JK, Surh YJ. Inflammation. Gearing the journey to cancer. Mutat. Res.659(1–2),15–30 (2008).
  Medline CASGoogle Scholar
• 166  Sgambato A, Cittadini A. Inflammation and cancer. A multifaceted link. Eur. Rev. Med. Pharmacol. Sci.14(4),263–268 (2010).
  Medline CASGoogle Scholar
• 167  Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer. Macrophage migration inhibitory factor (MIF) – the potential missing link. QJM103(11),831–836 (2010).
  Medline CASGoogle Scholar
• 168  Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer115(10),2031–2040 (2009).
  Medline CASGoogle Scholar
• 169  Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med.5(3),181–191 (1999).
  Medline CASGoogle Scholar
• 170  Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ. Res.93(4),321–329 (2003).
  Medline CASGoogle Scholar
• 171  Lue H, Thiele M, Franz J et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene26(35),5046–5059 (2007).
  Medline CASGoogle Scholar
• 172  Esposito E, Cuzzocrea S. TNF-α as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr. Med. Chem.16(24),3152–3167 (2009).
  Medline CASGoogle Scholar
• 173  Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol.10(3),308–315 (2010).
  Medline CASGoogle Scholar
• 201  NCBI: Structure Summary MMDB 5509 www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?Dopt=s&uid=5509
  Google Scholar
• 202  NCBI: Structure Summary MMDB ID 21160 www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?Dopt=s&uid=21160
  Google Scholar